# Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

> **NCT01195922** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Dental and Craniofacial Research (NIDCR)** · enrollment: 37 (actual)

## Conditions studied

- Mouth Neoplasms
- Head and Neck Neoplasms
- Tongue Neoplasms
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT01195922
- **Lead sponsor:** National Institute of Dental and Craniofacial Research (NIDCR)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195922, "Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01195922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*